Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Schistosoma mansoni | P2X receptor subunit | 0.0128 | 0.0528 | 0.0412 |
Brugia malayi | DOMON domain containing protein | 0.0181 | 0.0831 | 0.1601 |
Echinococcus granulosus | p2X purinoceptor 4 | 0.0128 | 0.0528 | 0.0911 |
Schistosoma mansoni | hypothetical protein | 0.0317 | 0.1604 | 0.1501 |
Schistosoma mansoni | P2X receptor subunit | 0.0128 | 0.0528 | 0.0412 |
Trichomonas vaginalis | equilibrative nucleoside transporter, putative | 0.0046 | 0.0062 | 0.5 |
Echinococcus multilocularis | p2X purinoceptor 4 | 0.0128 | 0.0528 | 0.0991 |
Loa Loa (eye worm) | transcription factor SMAD2 | 0.0094 | 0.0331 | 0.0638 |
Entamoeba histolytica | nucleoside transporter, putative | 0.0046 | 0.0062 | 0.5 |
Loa Loa (eye worm) | D-ets-4 DNA binding domain-containing protein | 0.0057 | 0.0122 | 0.0235 |
Loa Loa (eye worm) | DOMON domain-containing protein | 0.0181 | 0.0831 | 0.1601 |
Schistosoma mansoni | memapsin-2 (A01 family) | 0.046 | 0.2417 | 0.2324 |
Brugia malayi | Ets-domain containing protein | 0.0057 | 0.0122 | 0.0235 |
Schistosoma mansoni | ets-related | 0.0172 | 0.0779 | 0.0665 |
Schistosoma mansoni | hypothetical protein | 0.0099 | 0.036 | 0.0241 |
Echinococcus multilocularis | peptidyl glycine alpha amidating monooxygenase | 0.0947 | 0.5187 | 1 |
Brugia malayi | Nucleoside transporter family protein | 0.0046 | 0.0062 | 0.0119 |
Echinococcus granulosus | p2X purinoceptor 4 | 0.0128 | 0.0528 | 0.0911 |
Brugia malayi | Fli-1 protein | 0.0172 | 0.0779 | 0.1501 |
Brugia malayi | DOMON domain containing protein | 0.0181 | 0.0831 | 0.1601 |
Brugia malayi | MH2 domain containing protein | 0.0094 | 0.0331 | 0.0638 |
Echinococcus granulosus | Mitotic checkpoint protein PRCC C terminal | 0.0099 | 0.036 | 0.0582 |
Echinococcus multilocularis | equilibrative nucleoside transporter protein | 0.0046 | 0.0062 | 0.0088 |
Brugia malayi | Copper type II ascorbate-dependent monooxygenase, C-terminal domain containing protein | 0.0947 | 0.5187 | 1 |
Trypanosoma brucei | RNA helicase, putative | 0.0317 | 0.1604 | 0.5 |
Echinococcus multilocularis | equilibrative nucleoside transporter 3 | 0.0046 | 0.0062 | 0.0088 |
Loa Loa (eye worm) | MH2 domain-containing protein | 0.0094 | 0.0331 | 0.0638 |
Giardia lamblia | Hypothetical protein | 0.0046 | 0.0062 | 0.5 |
Trichomonas vaginalis | equilibrative nucleoside transporter, putative | 0.0046 | 0.0062 | 0.5 |
Echinococcus multilocularis | p2X purinoceptor 4 | 0.0128 | 0.0528 | 0.0991 |
Echinococcus granulosus | peptidyl glycine alpha amidating monooxygenase | 0.0947 | 0.5187 | 1 |
Loa Loa (eye worm) | DOMON domain-containing protein | 0.0181 | 0.0831 | 0.1601 |
Loa Loa (eye worm) | hypothetical protein | 0.0049 | 0.0075 | 0.0145 |
Brugia malayi | hypothetical protein | 0.0046 | 0.0062 | 0.0119 |
Echinococcus multilocularis | p2X purinoceptor 4 | 0.0128 | 0.0528 | 0.0991 |
Trichomonas vaginalis | equilibrative nucleoside transporter, putative | 0.0046 | 0.0062 | 0.5 |
Echinococcus granulosus | GA binding protein alpha chain | 0.0057 | 0.0122 | 0.0117 |
Echinococcus multilocularis | Mitotic checkpoint protein PRCC, C terminal | 0.0099 | 0.036 | 0.0665 |
Loa Loa (eye worm) | DOMON domain-containing protein | 0.0181 | 0.0831 | 0.1601 |
Brugia malayi | Ets-domain containing protein | 0.0057 | 0.0122 | 0.0235 |
Echinococcus granulosus | p2X purinoceptor 4 | 0.0128 | 0.0528 | 0.0911 |
Brugia malayi | Copper type II ascorbate-dependent monooxygenase, C-terminal domain containing protein | 0.0467 | 0.2453 | 0.4729 |
Onchocerca volvulus | 0.0181 | 0.0831 | 1 | |
Loa Loa (eye worm) | STAT protein | 0.0066 | 0.0176 | 0.0339 |
Loa Loa (eye worm) | hypothetical protein | 0.0947 | 0.5187 | 1 |
Schistosoma mansoni | thyroid hormone receptor | 0.0121 | 0.0486 | 0.0368 |
Loa Loa (eye worm) | hypothetical protein | 0.0046 | 0.0062 | 0.0119 |
Schistosoma mansoni | thyroid hormone receptor | 0.0121 | 0.0486 | 0.0368 |
Schistosoma mansoni | P2X receptor subunit | 0.0128 | 0.0528 | 0.0412 |
Loa Loa (eye worm) | hypothetical protein | 0.0046 | 0.0062 | 0.0119 |
Brugia malayi | STAT protein, DNA binding domain containing protein | 0.0066 | 0.0176 | 0.0339 |
Schistosoma mansoni | peptidyl-glycine monooxygenase | 0.0947 | 0.5187 | 0.5127 |
Echinococcus multilocularis | thyroid hormone receptor alpha | 0.0121 | 0.0486 | 0.0908 |
Loa Loa (eye worm) | fli-1 protein | 0.0172 | 0.0779 | 0.1501 |
Schistosoma mansoni | peptidylglycine monooxygenase | 0.0947 | 0.5187 | 0.5127 |
Loa Loa (eye worm) | hypothetical protein | 0.0046 | 0.0062 | 0.0119 |
Trichomonas vaginalis | equilibrative nucleoside transporter, putative | 0.0046 | 0.0062 | 0.5 |
Brugia malayi | Copper type II ascorbate-dependent monooxygenase, C-terminal domain containing protein | 0.0947 | 0.5187 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0947 | 0.5187 | 1 |
Echinococcus multilocularis | GA binding protein alpha chain | 0.0057 | 0.0122 | 0.0205 |
Brugia malayi | DOMON domain containing protein | 0.0181 | 0.0831 | 0.1601 |
Brugia malayi | Copper type II ascorbate-dependent monooxygenase, N-terminal domain containing protein | 0.0481 | 0.2533 | 0.4884 |
Schistosoma mansoni | P2X receptor subunit | 0.0128 | 0.0528 | 0.0412 |
Onchocerca volvulus | 0.0181 | 0.0831 | 1 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
EC50 (functional) | > 4 uM | Effective concentration of the compound against Moloney sarcoma virus | ChEMBL. | 15916441 |
EC50 (functional) | = 8.5 uM | Effective concentration of the compound against human immunodeficiency virus type 1 | ChEMBL. | 15916441 |
EC50 (functional) | = 20 uM | Effective concentration of the compound against human immunodeficiency virus type 2 | ChEMBL. | 15916441 |
IC50 (functional) | > 250 uM | Cytostatic activity of the compound against L1210 cell line | ChEMBL. | 15916441 |
IC50 (functional) | > 250 uM | Cytostatic activity to the compound against Molt4/C8 cell line | ChEMBL. | 15916441 |
IC50 (functional) | > 250 uM | Cytostatic activity to the compound against CEM cell line | ChEMBL. | 15916441 |
IC50 (functional) | > 250 uM | Cytostatic activity of the compound against L1210 cell line | ChEMBL. | 15916441 |
IC50 (functional) | > 250 uM | Cytostatic activity to the compound against Molt4/C8 cell line | ChEMBL. | 15916441 |
IC50 (functional) | > 250 uM | Cytostatic activity to the compound against CEM cell line | ChEMBL. | 15916441 |
MCC (functional) | = 20 ug ml-1 | Minimal cytotoxic concentration to cause an alteration in C3H/3T3 cell line morphology | ChEMBL. | 15916441 |
MCC (functional) | = 20 ug ml-1 | Minimal cytotoxic concentration to cause an alteration in C3H/3T3 cell line morphology | ChEMBL. | 15916441 |
MIC (functional) | = 8 ug ml-1 | Minimum inhibitory concentration against 559 glycopeptide susceptible enterococci Enterococcus faecalis | ChEMBL. | 15916441 |
MIC (functional) | = 16 ug ml-1 | Minimum inhibitory concentration against 533 Staphylococcus epidermidis | ChEMBL. | 15916441 |
MIC (functional) | = 16 ug ml-1 | Minimum inhibitory concentration against 602 Staphylococcus haemolyticus | ChEMBL. | 15916441 |
MIC (functional) | = 16 ug ml-1 | Minimum inhibitory concentration against glycopeptide intermediate-resistant 3797 Staphylococcus aureus | ChEMBL. | 15916441 |
MIC (functional) | = 16 ug ml-1 | Minimum inhibitory concentration against glycopeptide intermediate-resistant 3798 Staphylococcus aureus | ChEMBL. | 15916441 |
MIC (functional) | = 16 ug ml-1 | Minimum inhibitory concentration against glycopeptide susceptible enterococci 568 Enterococcus faecium | ChEMBL. | 15916441 |
MIC (functional) | = 32 ug ml-1 | Minimum inhibitory concentration against glycopeptide resistant enterococci 569 Enterococcus faecium | ChEMBL. | 15916441 |
MIC (functional) | = 32 ug ml-1 | Minimum inhibitory concentration against glycopeptide resistant enterococci 560 Enterococcus faecalis | ChEMBL. | 15916441 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
1 literature reference was collected for this gene.